Skip to content
value.today

PURE Bioscience, Inc.

PURE
$9 Mlast known market cap, Jul 2023 — no current value
Compare
World rank
—
no current market cap
Revenue
$2 M
For year ending July-2026
Net income
$-2 M
-106.9% margin
SEC filing
Employees
10
As of October 29, 2026
SEC filing

PURE Bioscience, Inc. in brief

PURE Bioscience, Inc. is a listed company in the FMCG industry, based in El Cajon, California, USA. Its last known market value was $9 M (July 2023); there is no current figure. In the year to July 2026 it had sales of $2 M and a net loss of $2 M. It employs about 10 people. Its largest product and service lines by sales in 2026 were PURE Hard Surface (94%) and SILVERION (6%).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About PURE Bioscience, Inc.

We are dedicated to developing and commercializing proprietary antimicrobial products that address health and environmental challenges related to pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain Silver Dihydrogen Citrate, or SDC. This broad-spectrum, non-toxic antimicrobial agent is available in liquid form and various concentrations, distinguished by its superior efficacy, reduced toxicity, non-causticity, and the inability of bacteria to develop resistance.

Our SDC-based disinfecting and sanitizing products are registered with the United States Environmental Protection Agency, or EPA, the United States Food and Drug Administration, or FDA, and Health Canada. In addition to manufacturing and distributing these products, we also supply SDC-based formulations as raw material ingredients for personal care products.

From the company's annual report filed with the US SEC: read the report

PURE Bioscience, Inc. timeline

3 events, 1996–2020
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2003
  4. ✎
    Renamed Pure Bioscience
    Formerly Innovative Medical Services.
  5. 2020
  6. 💰
    Record revenue of $7 million
    FY2020, the highest of the 9 years on record.

Events of PURE Bioscience, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$5 M$10 M$15 M$21 M2023

World rank over time

▼ down 1,205 places since 2022
2022-01-07: #30541#30,54120222022-12-25: #30593#30,59320222023-07-30: #31746#31,7462023

Rank in USA: #5,415 (Jan 2022) · #5,440 (Dec 2022) · #5,458 (Jul 2023)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-106.9%
Operating margin
-89.7%
Return on equity
—
Liabilities / assets
637.8%
Net debt
$6M
Revenue growth
+5.5%
R&D / revenue
14.2%
Revenue per employee
$232 K
Profit per employee
$-248 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Jul 2019: revenue $2M, net income $-7M$2MFY19Fiscal year ending Jul 2020: revenue $7M, net income $0M$7MFY20Fiscal year ending Jul 2021: revenue $4M, net income $-2M$4MFY21Fiscal year ending Jul 2022: revenue $2M, net income $-3M$2MFY22Fiscal year ending Jul 2023: revenue $2M, net income $-4M$2MFY23Fiscal year ending Jul 2024: revenue $2M, net income $-3M$2MFY24Fiscal year ending Jul 2025: revenue $2M, net income $-2M$2MFY25Fiscal year ending Jul 2026: revenue $2M, net income $-2M$2MFY26
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Jul 2026$2M+5.5%$-2M$-2M-106.9%
Jul 2025$2M+12.2%$-2M$-2M-109.1%
Jul 2024$2M+4.8%$-3M$-3M-170.9%
Jul 2023$2M+3.3%$-4M$-4M-211.8%
Jul 2022$2M-51.1%$-4M$-3M-192.8%
Jul 2021$4M-46.5%$-2M$-2M-62.7%
Jul 2020$7M+262.3%$0M$0M0.0%
Jul 2019$2M—$-6M$-7M-342.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Jul 2026$-2M——$-0.02—
Jul 2025$-2M——$-0.02—
Jul 2024$-3M——$-0.03—
Jul 2023$-3M$0M$-3M$-0.04—
Jul 2022$-2M$0M$-3M$-0.04—
Jul 2021$-1M$1M$-2M$-0.03—
Jul 2020$1M$0M$1M$0.00—
Jul 2019$-3M$0M$-3M$-0.09—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$2M
Net income, trailing 12 months
$-2M
RevenueNet income
Three months to Oct 2024: revenue $1M, net income $-1M$1MOct ’24Three months to Jan 2025: revenue $0M, net income $-1M$0MJan ’25Three months to Apr 2025: revenue $0M, net income $-1M$0MApr ’25Three months to Jul 2025 (from the annual report): revenue $1M, net income $-0M$1MJul ’25Three months to Oct 2025: revenue $1M, net income $-0M$1MOct ’25Three months to Jan 2026: revenue $0M, net income $-1M$0MJan ’26Three months to Apr 2026: revenue $1M, net income $-1M$1MApr ’26Three months to Jul 2026 (from the annual report): revenue $1M, net income $-1M$1MJul ’26

Latest quarter to Jul 2026: revenue $1M (-13.2% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jul 2026.

SEC filings

Official filings of PURE Bioscience, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-2 M
Net income
$-2 M

For year ending July-2026 · source: SEC filing

Balance sheet

Total assets
$1 M
Total liabilities
$8 M
Total equity
$-6 M

As of July-2026

Insider trading at PURE Bioscience, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
26
since
PURE Bioscience, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Robert F. BartlettCEO, DirectorBuyindirect+50,000$0.160$8 K50,000Form 4
filed Bernard BlotnerDirectorBuyindirect+10,000$0.130$1 K10,000Form 4
filed Tom Y. LeeChief Executive Officer, Director, 10% ownerBuy+50,000$0.130$7 K5.00 MForm 4
filed IVan ChenDirectorGrant or award+300,000$0.150$45 K750,000Form 4
filed David RendallDirectorGrant or award+325,000$0.150$49 K402,371Form 4
filed Tom Y. LeeChief Executive Officer, Director, 10% ownerGrant or awardindirect+15.74 M$0.150$2.4 M29.14 MForm 4
filed Tom Y. LeeChief Executive Officer, Director, 10% ownerGrant or awardindirect+6.00 M$0.150$900 K6.00 MForm 4
filed Tom Y. LeeChief Executive Officer, Director, 10% ownerBuy+185,000$0.200$37 K4.95 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: PURE Bioscience, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 1-for-8 reverse split

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

PURE Bioscience, Inc. scorecard#

Passes 5 of the 14 checks that could be worked out: strongest in growth (4 of 6), weakest in financial health (0 of 3). Fiscal year 2026.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 6
    • ✓Revenue grew in the newest year5.5%Revenue up 5.5% in fiscal 2026.
    • ✓Revenue up more than 5% a year over three years7.5%7.5% a year over the three years to fiscal 2026.
    • ✓Faster growth over three years than its peers' median7.5%7.5% a year against FMCG's median of 0.4% (30 companies).
    • ✗Earnings per share grew in the newest year-0.02 vs -0.02Diluted EPS -0.02 in fiscal 2026 against -0.02 the year before (report's currency).
    • ✗Net income higher than five years earlier-$2 M-$2 M in fiscal 2026 against -$2 M in 2021.
    • ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2026.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2026.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
    • ✗Operating margin above its peers' median-89.7%-89.7% against FMCG's median of 5.3% (40 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-89.7%-89.7% in fiscal 2026 against -210.7% in 2023.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.27 at the end of fiscal 2026.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-5.1×Operating income -5.1 times interest in fiscal 2026.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.1%Diluted shares up 4.1% in fiscal 2026.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of FMCG, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2026#

Worked out from PURE Bioscience, Inc.'s statements, beside the median of FMCG.

PURE Bioscience, Inc.: main financial ratios in 2026
Ratio2026Median of peers
Operating margin-89.7%5.3%
Net margin-106.9%4.1%
Revenue growth, 3 years a year7.5%0.4%
Revenue growth5.5%1.4%

2of 8on the Piotroski tests of financial strength

  • Net loss of $2 million, the 6th loss-making year in a row.
  • Shareholders' equity is negative: -$6 million.
  • Operating income covers the interest bill only -5.1 times.
  • Liabilities due within a year exceed current assets (current ratio 0.27).

PURE Bioscience, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

PURE Bioscience, Inc.: statements by fiscal year
PeriodTrendFY 2026to Jul 31, 2026FY 2025to Jul 31, 2025FY 2024to Jul 31, 2024FY 2023to Jul 31, 2023FY 2022to Jul 31, 2022FY 2021to Jul 31, 2021FY 2020to Jul 31, 2020FY 2019to Jul 31, 2019FY 2018to Jul 31, 2018FY 2017to Jul 31, 2017
Income statement
Revenue2.32.22.01.91.83.76.91.91.81.8
Cost of revenue1.00.90.80.90.91.92.90.70.80.8
Gross profit1.31.31.21.01.02.14.01.2——
Research and development0.30.30.30.30.30.30.30.40.50.8
Selling, general and administrative3.13.34.04.34.1r4.03.76.4r5.25.2
Operating expenses3.43.64.34.94.74.44.06.8r8.87.8
Operating income−2.1−2.3−3.2−3.9−3.7−2.30.0−5.6−7.0−6.0
Interest expense and finance costs0.40.30.20.00.00.00.00.00.0—
Other non-operating income (expense)−0.4−0.1−0.2−0.00.2−0.00.0−1.0−0.4−0.3
Income tax0000r0.00.00.00.00.00.0r
Net income attributable to shareholders−2.5−2.4−3.4−4.0−3.5−2.30.0−6.6−7.4−6.3
Earnings per share, basic-0.02-0.02-0.03-0.04-0.04-0.030.00-0.09-0.11-0.10
Earnings per share, diluted-0.02-0.02-0.03-0.04-0.04-0.030.00-0.09-0.11-0.10
Shares, weighted average (basic)11611211211189878273——
Shares, weighted average (diluted)116112112111898785736763
Balance sheet
Cash and cash equivalents0.60.30.31.13.42.43.80.40.91.6
Receivables0.30.50.30.30.20.41.10.40.30.3
Inventory0.20.10.10.10.20.30.50.20.20.3
Current assets1.21.00.81.63.93.25.61.01.52.5
Property, plant and equipment0.00.00.00.20.60.70.30.40.50.5
Other intangible assets—————0.40.40.50.70.8
Total assets1.21.10.81.84.54.36.31.92.63.8
Accounts payable0.80.80.60.40.50.61.30.60.60.4
Current liabilities4.42.1r0.70.50.61.01.50.71.32.5
Non-current liabilities——2.91.0——————
Total liabilities7.66.23.71.60.61.01.50.71.32.5
Retained earnings−141−139−137−133−129−126−123−123−117−109
Shareholders' equity−6.4−5.1−2.90.33.93.34.81.21.31.3
Total liabilities and equity1.21.10.81.84.54.36.31.92.63.8
Shares outstanding1301121121121118787776863
Cash-flow statement
Depreciation and amortization0.00.00.10.10.20.20.20.20.30.3
Share-based compensation0.20.10.20.30.60.80.82.42.41.1
Cash from operating activities−1.7−2.0−2.5−3.3−2.4−1.20.7−3.0−3.9−4.6
Capital expenditure———−0.0−0.1−0.5−0.1−0.0−0.0−0.2
Intangible assets bought———————−0.0−0.0−0.0
Cash from investing activities———−0.0−0.1−0.5−0.1−0.0−0.0−0.2
Shares issued————3.5—2.81.7—1.0
Cash from financing activities2.02.01.81.03.50.22.82.63.11.2
Change in cash0.2−0.0−0.7−2.31.0−1.43.4−0.5−0.8−3.6
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jul 31, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What PURE Bioscience, Inc. sells: revenue by product line, fiscal 2026#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$2 M100%
  • PURE Hard Surface$2 M94%
  • SILVERION$0 M5.8%

Business segments

  • Single Reportable$2 M100%

Source: SEC annual report (XBRL data) · as of Jul 31, 2026

Events at PURE Bioscience, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 5 · New debt 3 · Unregistered share sale 5 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 13

PURE Bioscience, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Bylaws or fiscal year changed8-K
Results announced8-K
Directors and officers8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 29, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of PURE Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2016$1 MPrivate placement after listingUnder $2 million7equity, optionsSEC
Nov 2015$2 MPrivate placement after listing$2 to $10 million13equity, optionsSEC
Oct 2015$6 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Aug 2014$10 MPrivate placement after listing$2 to $10 million28equity, optionsSEC
Jan 2014$1 MPrivate placement after listingUnder $2 million15equitySEC
Dec 2013$1 MNo. 4Under $2 million8equitySEC
Oct 2013$2 MNo. 3$2 to $10 million40equitySEC
Aug 2013$1 MNo. 2Under $2 million22equitySEC
Oct 2010$2 MNo. 1$2 to $10 million11equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How PURE Bioscience, Inc. compares in FMCG

  • Revenue$2 M · higher than 2% of 104
  • Net margin-106.9% · higher than 3% of 103
  • Revenue growth5.5% · higher than 73% of 46

Peer comparison · FMCG

CompanyMarket capP/ENet marginRev. growth
PURE Bioscience, Inc.🇺🇸$9 M—-106.9%+5.5%
The Procter & Gamble Company🇺🇸$372.2 B23.2×18.2%+3.3%
L'Oréal S.A.🇫🇷$241.7 B33.3×13.9%+5.5%
Unilever PLC🇬🇧$135.7 B12.7×18.8%+0.3%
Colgate-Palmolive Company🇺🇸$74.8 B36.4×9.7%+1.4%
Hindustan Unilever Limited🇮🇳$52.2 B32.2×23.6%—
Reckitt Benckiser Group PLC🇬🇧$44.3 B10.2×22.4%+3.3%
Haleon plc🇬🇧$42.6 B19.4×15.1%+1.2%
The Estée Lauder Companies Inc.🇺🇸$39.6 B107.6×2.4%+5.0%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jul 30, 2023 (last known)
Annual results:
For year ending July-2026
Balance sheet:
As of July-2026
Employees:
As of October 29, 2026
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at PURE Bioscience, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show PURE Bioscience, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about PURE Bioscience, Inc.? Suggest a correction